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Abstract
Background: Cell fusion induced by polyethylene glycol (PEG) is an efficient but poorly controlled procedure for
obtaining somatic cell hybrids used in gene mapping, monoclonal antibody production, and tumour
immunotherapy. Genetic selection techniques and fluorescent cell sorting are usually employed to isolate cell
fusion products, but both procedures have several drawbacks.
Results: Here we describe a simple improvement in PEG-mediated cell fusion that was obtained by modifying the
standard single-step procedure. We found that the use of two PEG undertreatments obtains a better yield of cell
fusion products than the standard method, and most of these products are bi- or trinucleated polykaryocytes.
Fusion rate was quantified using fluorescent cell staining microscopy. We used this improved cell fusion and cell
isolation method to compare giant cells obtained in vitro and giant cells obtained in vivo from patients with
Hodgkin’s disease and erythroleukemia.
Conclusions: In the present study we show how to improve PEG-mediated cell fusion and that cell separation by
velocity sedimentation offers a simple alternative for the efficient purification of cell fusion products and to
investigate giant cell formation in tumor development.
1. Background
The study of cell fusion has gained momentum in mod-
ern cell biology through several lines of investigation
[1-3]. Somatic cell hybrids have been used by a number
of investigators to analyse the genetic basis of cancer
[4-7] and for gene mapping [8-11]. Cell hybridisation
provided the method for generating monoclonal antibo-
dies [12] and fusion of virus-transformed cells has been
instrumental in the isolation of transforming viruses [13].
Tumour-dendritic cell fusion technology is applied to
immunotherapy strategies [14-16]. The idea that cell
fusion plays a role in the transition from polyploidy to
aneuploidy and hence in tumour progression has been
the subject of several reviews [7,3], but experimental evi-
d e n c ei nf a v o u ro ft h i sh y p o t h e s i si sd i f f i c u l tt oo b t a i n .
A sn o t e db yB r e n d aM .O g l ei nar e v i e wo nc e l lf u s i o n ,
“the origin of a cell as the product of a fusion event can
be difficult or impossible to deduce” [2].
In previous investigations we have explored the possi-
bilities that lymphocyte-lymphocyte fusion plays a role in
the cytogenesis of giant polykaryons in Hodgkin’s disease
(HD) [17] and that erythroblast fusion might be a source
of giant polykaryons in erythroleukemia [18]. To further
investigate these hypotheses, it might prove useful to iso-
late in-vitro-generated cell fusion products and compare
giant cells obtained in vitro with those present in vivo, by
morphological and immunocytochemical methods using
anti- i monoclonal antibody. Poly-N-acetyllactosaminyl
structures (i-antigen) carry a variety of physiologically
and pathologically important carbohydrate antigens and
are presumed to have essential roles in the process of cel-
lular recognition, differentiation, malignant transforma-
tion and cancer metastasis [19].
Electrofusion [20] and PEG-induced chemical fusion
[21] are the two most popular methods to fuse cells, and
only recently have genetic methods been proposed [22].
PEG remains a widely used agent for cell fusion because of
its simplicity and low cost. However, it is known that PEG
can cause the uncontrollable fusion of multiple cells, lead-
ing to the appearance of giant polykaryons. In addition,
standard PEG-mediated cell fusion is poorly reproducible,
and different cell types have variable fusion susceptibilities.
In an attempt to overcome these technical problems, we
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substituting two PEG undertreatments.
Genetic selection techniques [23] and fluorescent cell
sorting [24,25] have been used to isolate cell fusion pro-
ducts, although both procedures have several drawbacks.
Cell separation by physical methods provides a possible
alternative when either the densities or radii of the cells to
be isolated are substantially different in the starting cell
fraction [26]. Because polykaryocytes generated by cell
fusion are larger than their parent cells [27], it follows that
velocity sedimentation should be an appropriate cell
separation method. A relative large spherical particle, such
as an animal cell, moving through an uniform stable med-
ium under the influence of the earth’s gravitational field,
rapidly attains a terminal constant sedimentation that
represent a balance between the gravitational force and
the resistance to movement in a fluid. Equating the two
forces, the terminal velocity V is equal to:
V=2 (ρc − ρm)gr2/9η
where rc is cell density, rm is the density of the med-
ium, r is the cell radius, h is viscosity of the medium and
gi st h ee a r t h ’s gravitational force. For most mammalian
cells having densities in the range 1.040-1.090 g/ml, the
difference in the term of rc - rm is usually small com-
pared to the differences in radius, which is squared in
equation: the sedimentation rate, therefore, is dependent
primary on cell size. This suggests that separation by
velocity sedimentation should be performed using a start-
ing fraction that contains cells of restricted density.
Thus, the aim of this work is two-fold: 1) to provide a
simple and efficient tool for obtaining cell fusion pro-
ducts and their isolation and 2) to offer preliminary evi-
dence that cell fusion might be involved in giant cell
formation in tumour pathology.
2. Materials and methods
2.1. Isolation of peripheral blood mononuclear cells
Peripheral blood cells were harvested from blood bank
buffy coats, and mononuclear cells were isolated by den-
sity gradient centrifugation on lymphoprep (1.077 g/ml).
Lymphocytes were further purified by overnight incuba-
tion in a tissue culture flask to deplete monocytes, which
strongly adhere to the plastic. Erythroblasts were isolated
from cord blood as previously described [28].
2.2. Cell labelling
For identification of fused cells, we divided the starting
cell sample into two fractions that were labelled with
either cell tracker green (CMFDA) or orange (CMTMR)
(Molecular Probes, Eugene, OR) fluorescent probes
according to the manufacturer’s instructions. These dyes
are fluorescent chloromethyl derivatives that freely
diffuse through the membranes of live cells, but once
inside the cell they are converted into membrane-imper-
meant reaction products, facilitating the identification of
cell fusion products. CMFDA and CMTMR exchange
minimally until the complete merger of two cells. Imme-
diately after fusion the two dyes remain separate, but
later a yellow fluorescence results from the mixing of
orange and green dyes in fused cells. Additionally, in
separated experiments, cells were labelled with Vydrant
DiI (Molecular Probes, Eugene, OR), according to the
manufacturer’s instructions, in order to follow the
sequence of events between the initial contact of cells
and their fusion. Vybrant DiI it’s a carbocyanine dye that
labels cell membranes with an orange colour. Stained
cells were continuously observed in phase contrast/fluor-
escent microscopy to monitor cell fusion.
2.3. PEG-induced cell fusion
PEG-mediated cell fusion was performed either in a single
step procedure or in two steps over an interval of 15 h.
Cells previously labelled with fluorescent probes were trea-
ted with 1 ml 35% PEG 6000 MW (Merck-Schuchardt,
Hohenbrunn, Germany) in RPMI 1640 medium (Sigma,
St. Louis, MO), pH 8.2, for an exposure time of either 3 or
5 or 8 minutes (single step procedure) in a water bath at
37°C. During this time, the tube was gently swirled to keep
cells in suspension.
10 ml MEM (Minimal Essential Medium, Sigma, St.
Louis, MO) containing DNase was added in 10 mins by
continuous flow through a peristaltic pump. DNase was
added to prevent cell clumping. Cells were then centri-
fuged to remove PEG, washed twice in RPMI 1640, and
resuspended in complete medium (RPMI 1640 + 10%
fetal calf serum + 2 mM glutamine, penicillin, and strep-
tomycin). For the two steps procedure, labeled cells were
initially treated for 3 minuts with with 1 ml 35% PEG
6000 MW in a water bath at 37°C using the same proto-
col. After overnight incubation at 37°C/5% CO2, PEG
treatment was repeated for 5 min using the same
protocol.
After each PEG treatment, cell fusion products were eval-
uated and counted by cytochemistry and phase contrast/
fluorescence microscopy. Cell viability was determined by
trypan blue exclusion. Photographic documentation was
obtained using Zeiss fluorescence microscope and a Leica
confocal microscope TCS SP2.
2.4. Cell co-culture
Cell culture was performed in Transwell 6-well co-culture
chambers (Costar, Cambridge, MA) as previously
described [29]. These chambers were designed so that the
lower compartment, where a first cell population is placed
in culture, is separated from the upper compartment by a
0.45-μm microporous membrane permeable only to
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eral blood mononuclear cells (PBMC) from HD patients
were seeded, while the upper compartment contained
either an autologous single-cell suspension from a HD
[30] lymph node obtained for diagnostic purposes or an
Epstein Barr virus producing cell line (Burkitt’sl y m p h o m a
derived line P3HR-1, Human Tumor cell Bank-HTB).
2.5. Separation of cell fusion products by velocity
sedimentation
For cell separation by velocity sedimentation, we used a
sedimentation chamber previously described for the isola-
tion of Reed-Sternberg cells [31]. The separation chamber
was filled from the bottom with a linear gradient (1% -
3%) of human albumin in RPMI, generated with a gradient
mixer and peristaltic pump. The gradient was under-
layered with a dense liquid, immiscible with water (Fluori-
nert, 3M Co, St Paul, MN) that brought the gradient up to
the top of the sedimentation chamber (Figure 1).
Next, the cell sample was introduced into the chamber
and onto the gradient by reversing the peristaltic pump,
thus lowering the cell sample to the cylindrical part of the
device. This procedure deposits a very thin band (less than
1 mm) of an undisturbed cell suspension onto the gradi-
ent. Cells were allowed to sediment at unity gravity for
3 h, and then sequential fractions of 25 ml each were col-
lected from the bottom of the sedimentation chamber.
The percentages of mono-, bi-/tri-, and polynucleated
cells in each fraction were evaluated by cytochemistry and
fluorescence microscopy.
2.6 Culture in vitro of isolated cell fusion products and
immunofluorescent labelling
Following separation by velocity sedimentation, fused cells
were incubated at 37°C in tissue culture medium. Samples
were seeded in a classical clonogenic assay in semisolid
medium. Briefly, 2 × 10
4 cells were plated in 30 mm Petri
dishes in 1 ml aliquot of IMDM in the presence of 30%
FCS, 10 ng/ml IL-3, and 0.9% methylcellulose (w/v). After
4 weeks colonies were located under an inverted micro-
scope, individually picked up, washed and rendered into a
single cell suspension before being cytocentrifuged. Immu-
nostaining with anti-i was performed as previously
described [32]. Slides were inc u b a t e do v e r n i g h t ,a t4 ° C ,
with monoclonal antibody anti-i diluted 1:200 followed by
incubation with secondary monoclonal anti-IgM-TRITC.
Nuclei were counterstained by DAPI (4’,6-diamini-dino-2-
phenylindole) for 5 minute at room temperature.
3. Results
3.1. Cell fusion
Table 1 shows fusion rates for a homogeneous sample of
lymphocytes using different times of PEG treatment.
Experiments with a single PEG exposure showed poor
fusion efficiency when a short fusion time was used.
When the fusion time was increased, large sincytias with
many nuclei appeared and cell viability substantially
decreased. Differently when a two-steps PEG undertreat-
ment procedure was used, the fusion efficiency improved
as shown in Table 2. The highest rate of fusion was
obtained using a homogeneous population of lympho-
cytes, while erythroblasts had intermediate fusion ability.
An unexpected result using this approach is that most
fusion products were bi- or tri-nucleated cells. Giant mul-
tinucleated cells (5-10 nuclei) were consistently less than
2% of the cell population after the first PEG undertreat-
ment step. Microscopic observation of cell fusion after the
two-step procedure showed that 16-24% of lymphocytes
were physically fused. A mean number of 1,000 cells were
counted using phase contrast/fluorescent microscopy.
3.2. Microscopic examination of fused cells
After the first PEG undertreatment, we observed in cyto-
centrifuged preparations several cells in close contact,
sometimes connected by microspikes to touch and adhere
to adjoining cells (Figure 2a-b), as previously described
by others [33], but few fusion products (Figure 2c). The
second morphological feature of early fusion are intercel-
lular bridges closely resembling similar morphological
structures we observed in bone marrow cells from an ery-
throleukemia patient [18], suggesting cell fusion (Figure
2d) and in single cell suspension from lymph node affected
by Hodgkin’s disease (Figure 2e).
To further characterize the sequence of events follow-
ing the initial contact of cells, we monitored continu-
ously the morphological changes during fusion of
individual cell. Cells, stained by Vybrant DiI, made
initial contact (Figure 2f) and didn’t experience observa-
ble morphological changes during several minutes. Then
cells enlarged slightly and the boundary between two
cells began to disappear (figure 2g) and was completed
within two-three minutes leading to rounding of the
fusion product (figure 3h).
Figure 1 Isolation of cell fusion products by velocity
sedimentation. After three hours a clear-cut separation is obtained
between polykaryocytes and mononuclear cells.
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individual cells, one stained by CMFDA and the other by
CMTMR, is shown in Figure 3a. The two dyes produce a
yellow colour only when there’s a balanced quantity of
the two dyes and when viscosity of the cytoplasm allows
a balanced mixing of the dyes. This same cell type was
observed by confocal microscopy using different excita-
tion/recording laser lines appropriate for the two dyes
(Figure 3b-d).
After the second PEG undertreatment many cell fusion
products were readily observed (Figure 4a-b). Most cell
fusion products were bi-trinucleated homokaryocytes or
heterokaryocytes while a small percentage were giant
polykaryons, some with nuclei arranged along the periph-
ery of the cell (Figure 5c). Wreath-like giant cells can be
frequently observed in HD lymph nodes (Figure 5a) and
we have obtained morphological similar cells when
PBMC were co-cultivated either with an autologous sin-
gle-cell suspension of HD lymph node (Figure 5b) or
with the P3HR-1 cell line (Figure 5e), in a Transwell co-
culture chamber where the two cell populations are sepa-
rated by a 0.45-μm microporous membrane. In Figure 5b
arrow shows several cells in the process of fusing, close
to a giant polykaryon, morphologically resembling a cyto-
logical pattern observed in Figure 1e. If this morphologi-
cal pattern represents sequential steps of a fusion process
is presently suggestive, but remains to be proved. Similar
cells were also observed in erythroleukemia bone marrow
(Figure 5d).
3.3. Isolation of cell fusion products
Fused cells were isolated by velocity sedimentation.
After 3 h of sedimentation, cell fusion products were
recovered in the fast-moving fractions (Table 3). Poly-
karyons with several nuclei (4-6) were almost exclusively
obtained in the first fraction, while later fractions con-
tained mostly bi- or trinucleated cells. The mononuclear
unfused cell fraction moved at the sedimentation velo-
city of 6 mm/h, and a clear-cut separation between the
slow moving and fast moving cell fractions was always
obtained. The accuracy of the enrichment procedure
was evaluated by counting a mean number of 1,000 cells
per sample (Figure 6a-b).
3.4 Immunostaining of cell fusion products
After in vitro culture of cell fusion products obtained
from lymphocytes isolated from adult peripheral blood,
the majority of colonies were i-Ag negative while few of
them were positive when stained with anti-i monoclonal
antibodies (Figure 7a-b), the proportion of i-Ag positive
cells didn’t change with longer in vitro culture.
4. Discussion
The frequency of cell-cell fusion events induced by PEG
using standard conditions is usually low, and this quan-
titative limitation can impede subsequent investigations.
Therefore, we wished to develop an improved method
for PEG-mediated cell fusion that yields a higher num-
ber of cell fusion products.
Table 1 Cell fusion after a single PEG treatment using three different times of PEG exposure: mean ± standard
deviation.
Time of PEG-
exposition
Cell sample Lymphocytes (×
10
6)
Survival
(%)
Cell fusion products
(%)
Bi-trinucleated cells
(%)
Polynucleated cells (5-8
nuclei) (%)
3 min. 94.22 ± 5.4 77.2 ± 1.98 1.93 ± 0.08 1.87 ± 0.13 0.22 ± 0.42
5 min. 94.7 ± 6.15 47 ± 4.06 5.84 ± 1.51 2.93 ± 0.85 2.94 ± 0.82
8 min. 93.64 ± 4.87 21.9 ±1.95 12.06 ± 4.68 2.9 ± 0.52 8.88 ± 4.1
1000 cells were counted in phase contrast microscopy (data from 10 experiments).
Table 2 Fusion of homologous and non-homologous cells: mean ± standard deviation.
Cell
sample
Number of cells
(× 10
6)
Bi-tri nucleated cells
(%)
Poly nucleated cells
(%)
Single-dye polykaryocytes
(%)
Dual-dyes polykaryocytes
(%)
Ly-Ly
1
st step
98 ± 3.4 1.3 ± 0.8 0.11 ± 0.22 1.44 ± 0.24 0.35 ± 0.04
Ly-Ly
2
nd step
17.9 ± 0.6 79.61 ± 0.86 8.9 ± 5.2 9.5 ± 1.2 7.73 ± 2.5
Er-Er
1
st step
1 ± 0.06 0.76 ± 0.01 1.04 ± 0.8 0.74 ± 0.05 0.33 ± 0.66
Er-Er
2
nd step
7.02 ± 0.11 3.3 ± 0.5 2.9 ± 0.95 2.8 ± 1.09 1.44 ± 0.87
Ly-Mo
1
st step
99 ± 0.91 0.48 ± 0.05 0.24 ± 0.01 0.25 ± 0.09 0.22 ± 0.03
Ly-Mo
2
nd step
70.07 ± 1.85 2.23 ± 0.02 1.75 ± 0.84 1.63 ± 0.78 0.71 ± 0.06
1000 cells were counted in phase contrast microscopy and in fluorescent microscopy using a filter set appropriate for both emission wavelenghts (CMFDA and
CMTMR). (Data from 10 experiments. Ly, lymphocyte; Er, erythroblast; Mo, monocyte.). Single-dye polykaryocytes result from the fusion of cells stained by the
same fluorescent dye, while dual-dye polykaryocytes result from the fusion of cells stained bt two different fluorescent dyes.
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Page 4 of 10Figure 2 Cells after the first PEG undertreatment (May-Grünwald Giemsa staining). Intercellular bridges (black arrows) were clearly visible:
(a) lymphocytes (400×), (b) erythroblasts (800×). One fusion product (white arrow) was present (c) among single cells (green and red), as
observed by fluorescent and phase contrast microscopy (500×). (d) Intercellular bridges between erythroblasts (arrow) in a bone marrow smear
from a case of erythroleukemia (500×). (e) Single cell suspension from a lymph node affected by Hodgkin’s disease (500×). (f) Membrane
apposition, (g) triggering of fusion, (h) membrane coalescence, in cells stained by Vybrant DiI (500×).
Pedrazzoli et al. Cancer Cell International 2011, 11:32
http://www.cancerci.com/content/11/1/32
Page 5 of 10PEG damages cells. Consequently, the success of fusion
depends at least to some extent on minute details such as
the size and shape of the cell pellet, the intensity of shak-
ing, and other factors that are difficult to standardize.
PEG’s effect on cells is mainly secondary to dehydration
forces bringing the cells together. However, at least at a
lipid interface, PEG changes the orientation and configura-
tion of molecular dipoles and the organization of water
molecules associated with the membrane. Thus, PEG
probably induces changes in cell membrane permeability
and in the properties of its cytoskeletal components,
which may explain the cell rounding observed during
fusion. PEG overtreatment results in excessive cell death
and the formation of sincytia containing several nuclei,
while undertreatment results in insufficient fusion.
Our strategy to improve PEG-induced cell fusion was
suggested by the two-step electrofusion technique, which
first accomplishes cell membrane breakdown by a high-
intensity direct current pulse, followed by a second pulse
that induces cell fusion. Similarly, we adopted a two-step
approach to PEG-induced cell fusion. Using two under
treatments with 35% PEG for 3 min instead of the stan-
dard single 50% PEG treatment for 5 min, we were able
to obtain a high yield of cell fusion products. Importantly,
most of these fusion products were bi- or trinucleated
cells.
Once we had devised a method to improve PEG-
mediated cell fusion, we addressed the problem of iso-
lating cell fusion products. Genetic selection techniques
such as the HAT (hypoxanthine, aminopterin, thymi-
dine) system have been employed to isolate cell fusion
products [12], although there are several practical and
theoretical problems associated with their use. For
example, only special cell lines that lack the required
enzymes can be used. A second limitation is that
Figure 3 A representative image of a cell fusion product,
lymphocyte-lymphocyte, (a) observed in fluorescence
microscopy (800×), using a dual band filter for both emission
wavelenghts of CMTMR and CMFDA. This same cell type was
observed using a Leica TCS SP2 confocal microscope. The green
fluorescent emission was recorded between 500/530 nm (c) and the
red one between 570/620 nm (d). The colocalization of the two
colours in the fusion product is evidenced by the emission of both
the green and red fluorescence at the same plane (b and e).
Figure 4 Lymphocytes after the two-step fusion procedure and
before separation by velocity sedimentation. (a) Cells were
cytocentrifuged on a glass slide and stained by May-Grünwald
Giemsa. Bi- and trinucleated cells (black arrows) were readily
observed (800×). (b) Cell fusion products, in vivo, were transferred
into an Iwaki quartz base dish and observed by inverted fluorescence
microscopy using a dual filter (485/515 nm and 578/610 nm) and by
phase contrast microscopy (500×). One fusion product, at the
bottom, is entirely green (two CMTMR-labeled cells fused) while the
three fusion products (white arrow) in the centre-left are yellow (one
CMTMR-labeled cell fused with a CMFDA-labeled cell). The mixing of
the two fluorescent dyes takes some time and it is mainly dependent
on temperature and the viscosity of cell cytoplasm. Yellow
fluorescent is evident only when the two fluorescent dyes, CMTMR
and CMFDA, are completely mixed.
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Page 6 of 10Figure 5 (a) Histological section of a lymph node from a case of mixed cellularity HD. A Reed-Sternberg cell with nuclei arranged in a
circular fashion at the cell periphery is observed in the centre of the picture (200×). (b) Giant polykaryon obtained in vitro when peripheral
blood mononuclear cells (PBMC) from an HD patient were co-cultivated with a single cell suspension from the same patient in a Transwell co-
culture chamber. The two cell samples are separated by a 0.4-μm microporous membrane permeable to viruses and cytokines. At lower left is a
giant polykaryon, and at upper right are several cells in the process of fusing (400×). (c) Giant polykaryon observed after two-step PEG treatment
(800×). (d) Giant polykaryon (white arrow) in a bone marrow smear from a case of erythroleukemia (200×). (e) Giant polykaryon from PBMC co-
cultivated with P3HR-1 subline in a Transwell co-culture chamber (800×).
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genetic selection systems depend on the ability of the
fusion product to divide in selective medium. The
inability to utilize genetic selection techniques for nor-
mal cells represents a limitation for many studies, such
as the production of immunovaccines for tumour
immunotherapy by dendritic-tumour cell fusion [34-36].
Flow cytometry has been offered as an alternative
approach to quantifying and isolating hybrid cells after
fusion. Dot plot-type fluorescence-activated cell sorting
shows a quadrant in which a fluorescently coloured
probe monitors one cell type, and a second coloured
probe tracks a second cell type. A dually staining “fusion”
quadrant is considered demonstrative of fusion. However,
this evidence is not conclusive because aggregated cells
and single cells coated with cell debris can appear in this
“fusion” quadrant. Indeed, confocal microscopy con-
firmed these difficulties and proved to be superior to
flow cytometry in detecting cell hybrids [25].
On the basis of these theoretical considerations, it
seemed useful to isolate polykaryocytes, after PEG
fusion, by procedures independent from genetic selec-
tion or fluorescent tracking. Cell separation by physical
methods is an alternative approach to isolating these
polykaryocytes.
The theory underlying cell sedimentation holds that the
rate of sedimentation is largely a function of cell size, sug-
gesting velocity sedimentation as an appropriate method
for purifying cell fusion products [27]. Accordingly, we
found that separation of bi- and trinucleated cells was
excellent due to their larger size than parent cells.
During this investigation, we made the accidental obser-
vation of some similar morphological features between in-
vitro-fused cells and polykaryons we previously observed
in HD [29] and erythroleukemia [18]. Intercellular bridges
were frequently observed after the first step of PEG under-
treatment (Figure 1a-b) that closely resembles analogous
structures present in a bone marrow preparation from an
erythroleukemia patient (Figure 1d). Furthermore, large
multinucleated cells with nuclei arranged in a circular
fashion along the cell periphery can be observed both in
vivo (in erythroleukemia and HD) and in vitro under dif-
ferent experimental cell fusion conditions (Figure 4). Jin
has described similar cells in experiments when human
kidney epithelial cells were exposed to chronic activation
of protein kinase B [37] and by McShane while investigat-
ing EBV-induced cell fusion [38].
Hodgkin and Reed-Sternberg cells (HRS cells) are
believed to originate from B cells, but their phenotypic
pattern is very heterogeneous. B lineage markers such as
CD20, B-cell receptor, and CD79a are found only rarely
Table 3 Isolation of lymphocyte-lymphocyte fusion products by velocity sedimentation, mean ± standard deviation
Cell isolation by velocity sedimentation Mononucleated cells (%) Bi-tri nucleated cells (%) Polynucleated cells (%)
Fractions I 0.44 ± 0.75 0.48 ± 0.63 98.88 ± 1.01
II 0.21 ± 0.20 5.09 ± 0.87 95.97 ± 0.67
III 3.81 ± 0.83 95.94 ± 0.82 0.33 ± 0.72
IV 87.06 ± 0.85 13.16 ± 0.85 0.2 ± 0.11
1000 cells were counted in phase contrast microscopy and in fluorescent microscopy using a filter set appropiate for both emission wavelenghts (CMFDA and
CMTMR). (Data from 10 experiments.)
Figure 6 (a) Cell fusion products isolated by velocity
sedimentation (fraction III) and stained by May-Grünwald
Giemsa (400×) after cytocentrifugation, and (b) observed, in
vivo, by fluorescence microscopy (500×) using a dual filter
(485/515 nm and 578/610 nm) Cell tracker green (CMFDA) and
orange (CMTMR) can still be observed after fusion; a yellow
fluorescence develops only after cytoplasmic mixing.
Figure 7 Staining for i-Ag of cells retrieved from in vitro
culture of cell fusion products after PEG-induced cell fusion of
lymphocytes. a. DAPi staining of nuclei b. Not all cells are i-Ag
positive when stained with anti-i followed by incubation with
secondary monoclonal anti-IgM-TRITC.
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expression sharply distinguishes them from their healthy
counterparts. Whether this results from a) mutations
within the rearranged immunoglobulin genes or non-
functional rearrangements that prevent expression of
these genes [39], or b) the extinction phenomenon that
takes place when two cells fuse [40,41]., remains an
unanswered question.
Overall, the peculiar morphology and immunopheno-
type of HRS cells in infectious mononucleosis, HD, and
other diseases are still a mystery. If cell fusion plays a role
in giant cell formation in HD is presently only a tempting
hypothesis that is difficult to prove [2]. In infectious
mononucleosis and in several cases of HD, Reed-Sternberg
cells can be linked to infection with Epstein-Barr virus, a
fusogenic agent. Stepwise transformation of virus-infected
cells, possibly triggered by inherent genetic instability,
might lead to aneuploidy and cancer [42]. The correlation
between aneuploidy and cancer has been known for
decades; however, the central question of whether aneu-
ploidy results from cell fusion or abortive mitosis is still
unanswered.
Altered expression pattern for the I/i antigens have often
been observed during oncogenetic processes as well as in
benign haemopoietic disorders [43] Poly-N-acetyllactosa-
minyl, I (branched structure) and i (linear structure) struc-
tures, are important carbohydrate antigens and are
presumed to have essential roles in the process of cellular
recognition, differentiation [44], malignant transformation
and cancer metastasis, they are also expressed in carci-
noma cells in several tissues and organs [45]. The i/I tran-
sition in cell differentiation is determined by the
transcription factor CCAAT/enhancer binding protein
alpha (C/EBPalpha), which enhances transcription of the
IGnTC gene, consequently leading to formation of the I
antigen. The loss of function of C/EBPalpha has leukemo-
genic potential by remodelling the transcription network
of B cells through a series of parallel and sequential
changes that require endogenous PU.1 [46].
With this in mind we investigated the i/I antigen
expression in cell fusion products of lymphocytes isolated
from peripheral blood and kept in vitro culture for pro-
longed time. The presence of i-antigen positive colonies
suggest that cell fusion interferes with normal differentia-
tion and gene expression. Microarray technology is a
powerful tool that can quantify the expression of thou-
sands of genes in a single analysis. It has the potential to
monitor chromosome gains and losses, accomplish DNA
resequencing, and detect mutations, allowing more
intense probing of the mechanisms of tumour develop-
ment. A “census of human cancer genes” was compiled
that lists selected cancer genes having a causal link to
mutation and oncogenesis [47]. Using a microarray
approach to compare Reed-Sternberg cells obtained in
vivo and similar cells obtained in vitro might contribute
to unravelling the enigma if cell fusion plays a role in
Reed-Sternberg cell cytogenesis.
In conclusion, we have introduced some technical
improvements in PEG-mediated cell fusion and in the iso-
lation of cell fusion products that might prove useful in
the study of human malignancy, in the field of gene map-
ping, and we have offered preliminary evidence that cell
fusion might be involved in giant cell formation in HD.
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